How should I evaluate and manage a 23‑year‑old woman with persistent headaches that have not responded to ibuprofen?

Management of Persistent Headaches After Failed Ibuprofen Therapy

A 23-year-old woman with headaches unresponsive to ibuprofen should be evaluated for migraine and treated with a triptan (sumatriptan 50–100 mg or rizatriptan 10 mg) combined with an NSAID (naproxen 500 mg) for moderate-to-severe attacks, while limiting acute medication use to ≤2 days per week to prevent medication-overuse headache. 1

Initial Assessment and Red-Flag Exclusion

Before initiating treatment escalation, perform a focused evaluation to exclude secondary causes:

• Screen for red-flag features including thunderclap onset (sudden, severe headache), progressive worsening over days to weeks, new neurological deficits (weakness, vision changes, speech difficulty), fever with neck stiffness, recent head trauma, or age >50 with new-onset headache. 1
• Neuroimaging (MRI preferred) is indicated only when red-flag features are present; routine imaging for typical recurrent headache without concerning features is discouraged to avoid unnecessary radiation exposure and incidental findings. 1
• Confirm the diagnosis of migraine by assessing for unilateral location, pulsating quality, moderate-to-severe intensity, aggravation by routine activity, and associated symptoms (nausea/vomiting or photophobia/phonophobia). 1

Acute Treatment Algorithm After NSAID Failure

Step 1: Escalate to Triptan Therapy

• Initiate a triptan as first-line therapy for moderate-to-severe migraine or after ibuprofen has failed in 2–3 headache episodes. 1
• Sumatriptan 50–100 mg or rizatriptan 10 mg are the preferred oral triptans based on robust efficacy data; sumatriptan eliminates pain in 20–30% of patients by 2 hours. 1, 2
• Combination therapy (triptan + NSAID) is superior to either agent alone: adding naproxen 500 mg to sumatriptan provides 130 additional patients per 1,000 achieving sustained pain relief at 48 hours (number-needed-to-treat = 3.5). 1
• Administer medication early when pain is still mild: early treatment results in approximately 50% of patients pain-free at 2 hours versus 28% when delayed until pain is moderate-to-severe. 1

Step 2: Alternative Triptan Formulations if Oral Route Fails

• Intranasal sumatriptan 5–20 mg or subcutaneous sumatriptan 6 mg should be considered when significant nausea/vomiting is present or when oral triptans are ineffective. 1
• Subcutaneous sumatriptan 6 mg provides the highest efficacy (59% complete pain relief by 2 hours) with onset within 15 minutes, making it ideal for rapidly progressive attacks. 1

Step 3: Third-Line Options After Triptan Failure

• If multiple triptans fail after adequate trials (2–3 episodes each), escalate to CGRP antagonists (ubrogepant 50–100 mg or rimegepant) or lasmiditan 50–200 mg (a 5-HT₁F agonist without vasoconstriction). 1
• Lasmiditan is safe in patients with cardiovascular risk factors but requires avoiding driving or operating machinery for at least 8 hours after dosing due to CNS effects (dizziness, somnolence). 1, 2

Critical Medication-Overuse Prevention

• Limit all acute migraine medications to ≤2 days per week (≤10 days per month) to prevent medication-overuse headache, which paradoxically increases headache frequency and can lead to daily headaches. 1
• If headaches occur more than twice weekly, initiate preventive therapy immediately rather than increasing acute medication frequency. 1

When to Initiate Preventive Therapy

Preventive treatment is indicated when:

• ≥2 migraine attacks per month cause disability lasting ≥3 days. 1
• Acute medication use exceeds 2 days per week. 1
• Acute treatments are contraindicated or have failed after adequate trials. 1

First-Line Preventive Options

• Propranolol 80–240 mg/day (doses <160 mg are generally sub-therapeutic) has the strongest evidence among traditional preventives. 1, 3
• Topiramate 50–100 mg/day is the only oral preventive with robust RCT evidence for chronic migraine and is preferred when obesity is present due to associated weight loss. 1, 3
• Candesartan is especially useful when hypertension coexists. 3
• Allow an adequate trial of 2–3 months at target dose before judging efficacy; immediate benefits are rare. 1, 3

Medications to Absolutely Avoid

• Opioids (codeine, hydrocodone, oxycodone, tramadol) and butalbital-containing compounds are absolutely contraindicated for migraine treatment because they provide questionable efficacy, carry high dependence risk, precipitate rebound headaches, and worsen long-term outcomes. 1
• These agents should never be prescribed as rescue therapy even when other treatments fail. 1

Contraindications to Triptans

• Triptans are contraindicated in patients with ischemic heart disease, uncontrolled hypertension (systolic >140 mmHg or diastolic >90 mmHg), cerebrovascular disease, history of stroke/TIA, or basilar/hemiplegic migraine due to vasoconstrictive properties. 1
• In patients with cardiovascular contraindications, use NSAIDs, CGRP antagonists (ubrogepant, rimegepant), or lasmiditan as alternatives. 1

Follow-Up and Monitoring

• Instruct the patient to maintain a headache diary (paper or smartphone app) to track attack frequency, severity, duration, medication use, and triggers; this improves accuracy of reporting and helps identify modifiable factors. 1
• Schedule follow-up within 2–3 months to assess treatment response, optimize dosing, and screen for medication overuse. 1
• Provide red-flag return precautions: seek emergent care for "worst headache of life," seizure, loss of consciousness, or new neurological deficits. 1

Common Pitfalls to Avoid

• Do not continue ibuprofen indefinitely without escalation; after 2–3 failed episodes, switch to triptan therapy. 1
• Do not prescribe opioids or butalbital compounds even when patients request them or report "nothing else works." 1
• Do not allow patients to increase acute medication frequency beyond 2 days per week; instead, transition to preventive therapy. 1
• Do not abandon triptan therapy after a single failed attempt; failure of one triptan does not predict failure of others—try alternative triptans or different routes of administration. 1